Loading organizations...
Mey Capital Matrix is an investment firm focused on the life science sector, providing capital and strategic management expertise to nascent companies. The firm specifically targets ventures with innovations in medical diagnostics and therapy, aiming to build a substantial portfolio of high-impact investments. Its strategy combines financial backing with hands-on guidance, drawing on the team's deep experience in corporate leadership and entrepreneurial mentorship.
Gerhard Mey, an accomplished entrepreneur with a background as a co-owner and supervisory board member in the automotive industry, established the firm. Mey founded Mey Capital Matrix driven by the critical role of life science innovation in addressing future societal challenges, seeking to foster promising companies in this vital field. He created a platform to apply his deep entrepreneurial and investment experience, thereby supporting new ventures from concept to market success.
The firm partners with life science founders possessing forward-looking ideas, guiding their progression from initial concept to successful enterprise. Mey Capital Matrix’s broader vision is to mitigate significant global issues like rising life expectancy and demographic shifts through advancements in life science. It endeavors to cultivate a supportive network among its portfolio companies, positioning itself as a dedicated entrepreneurial partner in achieving these long-range objectives.
Mey Capital Matrix has 3 tracked investments across 2 companies. The latest tracked deal is $13.8M Other Equity in iThera Medical in December 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 22, 2022 | iThera Medical | $13.8M Other Equity | Trumpf Venture | Baybg, EIC Fund, Falk Strascheg Holding, Fluxunit, Occident, Wachstumsfonds Bayern |
| Sep 2, 2019 | GNA Biosolutions | $13.5M Series C | TOM Miller | Bayern Kapital, Btov Partners, KFW, Occident, Robert Bosch Venture Capital, SHS Gesellschaft FÜR Beteiligungsmanagement |
| Jul 2, 2015 | GNA Biosolutions | $6.7M Series B | Robert Bosch Venture Capital | Btov Partners, KFW, SHS Gesellschaft FÜR Beteiligungsmanagement, Unternehmertum |